生物医药系列产品
数据
资源
版本对比
免费注册
预约演示
免费注册
Cyclacel Pharmaceuticals
Announces Preclinical Proof-of-Concept Data for
Fadraciclib
to be Presented at the American Association for
Cancer
Research (AACR) Annual Meeting 2024
2024-03-07
·
BioSpace
临床2期
临床1期
AACR会议
BERKELEY HEIGHTS, N.J., March 07, 2024 (GLOBE NEWSWIRE) --
Cyclacel Pharmaceuticals Inc.
(NASDAQ: CYCC, NASDAQ: CYCCP; "
Cyclacel
" or the "Company"), a biopharmaceutical company developing innovative medicines based on
cancer
cell biology, today announced that preclinical proof-of-concept data with the Company’s
fadraciclib
will be presented at the upcoming American Association for
Cancer
Research (AACR) Annual Meeting 2024, being held April 5-10 in San Diego, California. The data will be presented at three poster sessions and report activity and antitumor effects of
fadraciclib
in
biliary tract cancer
,
lung cancer
, Richter transformation and
lymphoma
cell lines. Details of the presentations are as follows: Title: The
CDK2/9 inhibitor
fadraciclib
is active in Richter transformation and
lymphoma
cell lines by targeting both cell survival and proliferation Abstract No: 518 / 15 Session Topic: Session PO.ET05.01 - Cell Cycle, Transcription Regulation, and Anticancer Drug Action Date and Time: April 7, 2024, 1:30 PM - 5:00 PM PT Location: Exhibition Hall, Section 21 Title: Elucidation of the fates of
CDK2
inhibited aneuploid and residual
lung cancers
Abstract No: 2117 / 8 Session Topic: Session PO.ET07.02 - Pharmacodynamic Biomarkers of Drug Response Date and Time: April 8, 2024, 9:00 AM - 12:30 PM PT Location: Exhibition Hall, Section 30 Title: Anti-
tumor
effects of
fadraciclib
,
CDK2/9 inhibitor
, in
biliary tract cancer
Abstract No: 5711 / 11 Session Topic: Session PO.MCB01.01 - Pharmacologic Targeting of Cell Cycle Proteins Date and Time: April 9, 2024, 1:30 PM - 5:00 PM PT Location: Exhibition Hall, Section 18 About Cyclin-Dependent Kinases and
Fadraciclib
Cyclin-dependent kinases (CDKs) are critical for cell cycle control and transcriptional regulation. Dysregulated
CDKs
have been linked to the
cancer
hallmarks of uncontrolled proliferation and increased
cancer
cell survival.
Fadraciclib
is a highly selective, potent, orally and intravenously available, next generation inhibitor of
CDK2
and
CDK9
. By inhibiting
CDK2
and
CDK9
fadraciclib
causes apoptotic death through anaphase catastrophe of
cancer
cells at sub-micromolar concentrations. To date single agent activity, including CR, PR and SD, has been observed in patients with advanced endometrial, squamous NSCLC lung cancer and
T-cell lymphoma
. Encouraging signals of activity were observed in patients with advanced cervical, hepatocellular, ovarian and pancreatic cancers. 065-101 Study of Oral
Fadraciclib
Oral
fadraciclib
is being tested in a Phase 1/2 trial for the treatment of
advanced solid tumors
and
lymphoma
(065-101; NCT#04983810). A total of 29 patients have been treated as monotherapy in this ongoing study. The study is enrolling unselected, all comer patients with
advanced solid tumors
and
lymphoma
. The Phase 2 part of the 065-101 study is designed to further evaluate fadra safety and efficacy in up to 8 cohorts defined by histology and/or NGS. The study is powered to demonstrate response in the molecular subtype suggested by the Phase 1 data and others that may be sensitive.
CDKN2A
,
CDKN2B
,
MTAP
deletions
CDKN2A
gene deletions occur in over 40% of several
solid tumors
, including
glioma
, head and neck, pancreatic, esophageal, lung (incl. squamous), bladder, melanoma, and others.
CDKN2B
deletions occur in over 30% of several
solid tumors
, including
bladder, glioma
, pancreatic, esophageal, lung (incl. squamous), head and neck, melanoma, and others.
MTAP
deletions occur in over 25% of several
solid tumors
, including
glioma
,
mesothelioma
, pancreatic, bladder, esophageal and others.
MTAP
deletion confers dependency on the
PRMT5
enzyme in
cancer
cells which was identified as a synthetic lethal target for
MTAP deleted cancers
MTAP
deleted cancers. About
Cyclacel Pharmaceuticals, Inc.
Cyclacel
is a clinical-stage, biopharmaceutical company developing innovative
cancer
medicines based on cell cycle, transcriptional regulation and mitosis biology. The transcriptional regulation program is evaluating
fadraciclib
, a
CDK2/9 inhibitor
, and the anti-mitotic program
CYC140
, a
PLK1 inhibitor
PLK1
inhibitor, in patients with both
solid tumors
and
hematological malignancies
.
Cyclacel
's strategy is to build a diversified biopharmaceutical business based on a pipeline of novel drug candidates addressing oncology and hematology indications. For additional information, please visit . Forward-looking Statements This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the efficacy, safety and intended utilization of
Cyclacel
’s product candidates, the conduct and results of future clinical trials, plans regarding regulatory filings, future research and clinical trials and plans regarding partnering activities. Factors that may cause actual results to differ materially include the risk that product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical trials, trials may have difficulty enrolling,
Cyclacel
may not obtain approval to market its product candidates, the risks associated with reliance on outside financing to meet capital requirements, the potential effects of the
COVID-19 pandemic
, and the risks associated with reliance on collaborative partners for further clinical trials, development and commercialization of product candidates. You are urged to consider statements that include the words "may," "will," "would," "could," "should," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties the Company faces, please refer to our most recent Annual Report on Form 10-K and other periodic and other filings we the Securities and Exchange Commission and are available at . Such forward-looking statements are current only as of the date they are made, and we assume no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. Contacts Company: Paul McBarron, (908) 517-7330, pmcbarron@cyclacel.com Investor Relations: Grace Kim, IR@cyclacel.com © Copyright 2024
Cyclacel Pharmaceuticals, Inc.
All Rights Reserved. The
Cyclacel
logo and
Cyclacel
® are trademarks of
Cyclacel Pharmaceuticals, Inc.
更多内容,
请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
机构
Cyclacel Pharmaceuticals, Inc.
Cyclacel Ltd.
适应症
肿瘤
胆道肿瘤
肺癌
[+8]
靶点
CDK2
CDKs
CDK9
[+5]
药物
Fadraciclib
LDC-9-A
CYC-140
[+1]
标准版
¥
16800
元/账号/年
新药情报库 | 省钱又好用!
立即使用
来和芽仔聊天吧
热门报告
罗氏双特异性抗体药物Emicizumab专利调研实务指南
智慧芽生物医药
特应性皮炎深度解析:药物开发、专利分析与风险评估
智慧芽生物医药
2024年7月全球首批及特殊审评药物报告
智慧芽生物医药
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
开始免费试用
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。
试用数据服务